List of Biotech, Pharmaceutical & Life Sciences companies in Hungary - 11

Avidin Ltd. was established in 2002. Avidin has started its drug discovery programme in 2007 in the field of cancer and infectious diseases. The company in-licensed an anti-cancer compound family interfering lipid vesicle formation and trafficking, a novel way to combat this disease. The company is developing novel approaches for high throughput gene expression analysis and screening technologies for drug discovery. Avidin has started focusing on chemical library synthesis in 2007 for patentable bioactive compounds. Avidin is the local distributor of several products related to different molecular biological methods: BioTrove (Woburn, MA, USA), Bioneer (Daeleon, Korea).

Cyclolab Cyclodextrin R&D Laboratory is the world's only all-round CYCLODEXTRIN BIOTECH company CycloLab Ltd. started its life and operated as a small R&D company for over 30 years. Recent changes in the world market and economy revealed the need for a change in the company’s business portfolio. Hence we have decided to share the resources between R&D activity and establishment of manufacturing facilities that enable the production of cyclodextrins in larger scale and under GMP circumstances. To maintain and strengthen our position in the market, CycloLab dedicates special attention to invention and developing patentable technologies. This attitude is well highlighted by the over 130 patents filed by the company so far. CycloLab committed its operations to serve the pharmaceutical industry by participating in early phase drug development studies (feasibility, formulation optimization, bioequivalence, etc), analysis and GMP manufacturing of various cyclodextrin derivatives to be applied as excipients.

We are one of the leading generic pharmaceutical companies in Central Eastern Europe, our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of Servier, a global pharmaceutical group governed by a Foundation. In the 2022/2023 business year Egis Group generated net sales of EUR 631.7 million. Besides Hungary, we sell our products under Egis’ brand names in 18 countries through our network of subsidiaries and representative offices. Our products (active ingredients, tablets, injections, galenic formulations etc.) are available in 100 countries in total through our network of subsidiaries, representative offices or partners. Our focus lies on treating diseases of the cardiovascular and central nervous systems and we also provide modern treatment solutions in the fields of diabetology, skin and wound care. In 2013, we launched our first biosimilar monoclonal antibody (mAb) product, it was also the first mAb in the European Union. Since then, we launched 3 more biosimilar drugs. As one of the companies in the CEE region committed to innovation, we devote more than EUR 45 million yearly to R&D. Our research and development activities focus on high-quality, value-added branded generic products. In the last 20 years, we have invested more than EUR 770 million in improvements in Hungary: we modernized the complete process of finished product manufacturing and established state-of-the-art R&D centres. In Budapest the development of drugs substances and finished products having significant biological activity in very small doses has become possible and the comprehensive modernization of the traditional technology of active ingredient manufacturing has been completed. Large-scale developments at our site in Körmend: inauguration of a new galenic plant (Sept 2019); the major extension of the packaging plant was completed and capacity to manufacture special medicines - typically oncology products - was established (both 2021 autumn).

Mediso is one of the World's largest suppliers of various medical diagnostic and research purpose, single and multimodality imaging devices. The company was founded in 1990 by experts in the largest research and manufacturing company in Europe which has been engaged of nuclear equipment development and production since 1960. Currently Mediso offers 4 imaging modalities - SPECT, PET, CT, MRI - for professionals working in laboratories and nuclear medicine departments. Mediso products are sold worldwide directly and through a network of distributors. There are more than 1650 imaging systems operating in more than 100 countries around the world.

Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 100 laboratories worldwide. Building on multidisciplinary competences in bioinformatics, software engineering, molecular biology and regulatory science, Omixon transforms molecular biology innovations into state-of-the-art products in transplant diagnostics. Omixon was the first to successfully introduce NGS-based HLA typing kit and software in 2014 by bringing Holotype HLA, an NGS-based HLA genotyping product, and HLA Twin software to market. Omixon Twin delivers the most accurate high-resolution HLA genotyping and is used in more than 100+ laboratories worldwide. Omixon was the first to release a high-resolution HLA genotyping product NanoTYPE HLA™ with less than 5 hours turnaround time on the Oxford Nanopore sequencing platform complemented by NanoTYPER™ analysis software. Omixon is the first to bring to market the first donor-derived cell-free DNA kit HoloGRAFT for laboratories with donor-informative genetic markers with primer and probe sequences that are absent in the patient genotype by design. On October 16, 2024, in Barcelona, Spain, Werfen announced the completion of its acquisition of Omixon, after securing all required regulatory and antitrust approvals.

Osmotica Pharmaceutical is a fully-integrated pharmaceutical company with demonstrated expertise in developing commercially successful products. As one of the world's leading osmotic drug delivery companies, we leverage our significant resources in R&D and proprietary drug delivery technology to address the growing need of the global patient population. We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.

More than a CRO, your creative R&D team™ www.pharmahungary.com Mission of Pharmahungary - providing wide range of innovative and cost-effective preclinical pharmacology R&D services focusing on cardiovascular (infarction, heart failure, stroke, sepsis, arrhythmias, etc) and metabolic diseases (diabetes, dyslipidemia, atherosclerosis, obesity, uremia, etc) with strong scientific support - clinical R&D services focusing on special clinical studies including medical device that need sensitive patient population and thereby strong regulatory & scientific support - to manage internal R&D projects to develop new technologies for outlicensing in the fileds of diagnosis and therapy of cardiovascular and metabolic diseases Why Pharmahungary? - Full service: creative, cost-effective, flexible, high quality - Internationally trained management & staff (MDs, PhDs, clinical pharmacologists, PharmDs, chemists, biologists, medical engineers, MBA quality managers) - Complex platforms of cardiovascular and metabolic disease models, - Custom design models with co-morbidities, including large animals - Strong biochemical and molecular biological background for complex proof-of-concept studies - Scientific support based on international scientific excellence (publications over 380, impact factors over 1 400, citations over 26 000) - Strict confidentiality, IP rights under regulations of the European Union For more information please visit: www.pharmahungary.com.

Customers come to Research Professionals CRO (RP-CRO) from across the globe for our dedication to delivering the most efficient, flexible, and highest quality GCP-compliant CRO services. RP-CRO leverages its extensive network of highly experienced Principal Investigators and their large local subject pools to accelerate study enrolment for a wide range of study types. Our CRO team focuses on efficiently driving your study to completion and preparing the highest-quality submissions for the regulatory authorities.

Solvo Biotechnology provides drug-drug interactions and drug transporter studies and assessment services for medical agencies.

Turbine develops an AI platform that simulates cancer behavior, designs effective therapies, and increases clinical success rates using digital cell models, cell behavior simulation technology, and molecular biology.

Ubichem partners with Pharmaceutical Innovators who trust Ubichem to provide ultimate customer value through technical, product and regulatory solutions. As a leading distributor, Ubichem partner with manufacturers across a global supply chain to offer customers an extremely diverse product range of outstanding APIs, Excipients, Intermediates and Fine Chemicals. Our leading portfolio of suppliers and solutions includes some of the most trusted names in the industry’s we serve, such as Symrise, Vanderbilt, Symbiotica, to name a few. With decades of product and application expertise combined with deep market trend analysis and regulatory knowledge we help our suppliers and customers to succeed. What’s more, through new product development, our customers benefit from significant commercial opportunities. And with agile manufacturing we provide a comprehensive end-to-end service of design and development, sourcing, conversion, warehousing, and distribution. We call it ‘Ultimate Customer Value’ and it’s in our DNA. For more information visit www.ubichem.com